Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Public ClinicalTrials.gov record NCT04745832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Study identification
- NCT ID
- NCT04745832
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Enrollment
- 82 participants
Conditions and interventions
Interventions
- Zandelisib Drug
- Rituximab Drug
- Bendamustine Drug
- CHOP Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2021
- Primary completion
- Mar 19, 2023
- Completion
- Mar 19, 2023
- Last update posted
- Nov 3, 2024
2021 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Oncology Institute of Hope and Innovation | Tucson | Arizona | 85745 | — |
| Orange Coast Memorial Medical Center | Fountain Valley | California | 92708 | — |
| Long Beach Memorial Medical Center | Long Beach | California | 90806 | — |
| The Oncology Institute of Hope and Innovation | Riverside | California | 92506 | — |
| BRCR Medical Center Inc | Hollywood | Florida | 33021 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Revive Research Institute | Farmington Hills | Michigan | 48334 | — |
| Revive Research Institute | Sterling Heights | Michigan | 48314 | — |
| Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center | Springfield | Missouri | 65804 | — |
| Inspira Medical Center Mullica Hill | Mullica Hill | New Jersey | 08062 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Alpha Research Institute, LLC | Baytown | Texas | 77521 | — |
| Valley Cancer Associates | Harlingen | Texas | 78550 | — |
| Community Cancer Trials of Utah | Ogden | Utah | 84405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 127 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04745832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04745832 live on ClinicalTrials.gov.